- Home
- RXT vs ANNX Comparison
RXT vs ANNX Comparison
Compare RXT & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXT
- ANNX
- Stock Information
- Founded
- RXT 1998
- ANNX 2011
- Country
- RXT United States
- ANNX United States
- Employees
- RXT N/A
- ANNX N/A
- Industry
- RXT EDP Services
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- RXT Technology
- ANNX Health Care
- Exchange
- RXT Nasdaq
- ANNX Nasdaq
- Market Cap
- RXT 524.5M
- ANNX 553.2M
- IPO Year
- RXT 2020
- ANNX 2020
- Fundamental
- Price
- RXT $2.45
- ANNX $4.17
- Analyst Decision
- RXT Hold
- ANNX Strong Buy
- Analyst Count
- RXT 6
- ANNX 7
- Target Price
- RXT $2.47
- ANNX $15.80
- AVG Volume (30 Days)
- RXT 761.3K
- ANNX 1.4M
- Earning Date
- RXT 03-11-2025
- ANNX 11-14-2024
- Dividend Yield
- RXT N/A
- ANNX N/A
- EPS Growth
- RXT N/A
- ANNX N/A
- EPS
- RXT N/A
- ANNX N/A
- Revenue
- RXT $2,771,200,000.00
- ANNX N/A
- Revenue This Year
- RXT N/A
- ANNX N/A
- Revenue Next Year
- RXT N/A
- ANNX N/A
- P/E Ratio
- RXT N/A
- ANNX N/A
- Revenue Growth
- RXT N/A
- ANNX N/A
- 52 Week Low
- RXT $1.45
- ANNX $3.86
- 52 Week High
- RXT $3.41
- ANNX $8.40
- Technical
- Relative Strength Index (RSI)
- RXT 53.77
- ANNX 30.75
- Support Level
- RXT $2.31
- ANNX $3.95
- Resistance Level
- RXT $2.53
- ANNX $4.99
- Average True Range (ATR)
- RXT 0.16
- ANNX 0.31
- MACD
- RXT 0.03
- ANNX -0.08
- Stochastic Oscillator
- RXT 61.82
- ANNX 12.87
About RXT Rackspace Technology Inc.
Rackspace Technology Inc is an end-to-end, hybrid, multi cloud technology services company. It designs, builds and operates its customers' cloud environments across all technology platforms, irrespective of technology stack or deployment model. The company's solutions include Application Services; Data; Colocation; Cloud; Managed Hosting; Professional Services; and Security & Compliance. It operates in segments namely, Private Cloud, and Public Cloud. It generates revenue through the sale of consumption-based contracts for its service offerings and from the sale of professional services related to designing and building custom solutions.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.